-
Study aim
-
Feasibility evaluation of secretome obtained from menstrual blood derived stem cells accompanied with melatonin and follicular fluid of non polycystic ovary syndrome patients in patients with polycystic ovary syndrome in order to improve oocyte maturation and assessment of embryos quality compared to control group.
-
Design
-
The clinical trial involves 4 groups including the control group plus 3 experimental groups in which the immature oocytes of 90 patients were non-randomly distributed.
-
Settings and conduct
-
The study will be performed at Avicenna Infertility Treatment Center on immature oocytes of polycystic ovary syndrome women.
Immature oocytes in the germinal vesicle (GV) stage, which are not clinically usable, will be collected post ovulation of the patients who filled informed consent. Matured oocytes will be assessed for the expression of maturation-related genes and apoptotic genes using Polymerase Chain Reaction (PCR).
-
Participants/Inclusion and exclusion criteria
-
Among infertile women who visit the clinic:
polycystic ovary syndrome women, ages under 40 yrs, Anti Mullerian hormone higher than 1.3, at least 4 immature oocytes and non male factor, are included.
Non polycystic ovary syndrome women, unable to give informed consent, immature oocytes under 4, Anti Mullerian hormone under 1.3, background disease and infectious disease hepatitis C virus, human immunodeficiency virus (HIV) and hepatitis B, will be excluded.
-
Intervention groups
-
The study groups involve 4 groups for each individual containing the routine medium used for oocyte culture in the laboratory as a control, stem cell secretome, the secretome and melatonin, the secretome and melatonin and the follicular fluid added to the routine medium.
-
Main outcome variables
-
Oocyte maturation, embryo development, embryo quality, expression of oocyte maturation related genes and expression of apoptotic genes.